Ultragenyx to Participate at Investor Conferences in London
NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.
Covered in this story
Analyst targets on Ultragenyx Pharmaceutical
- H.C. Wainwright: at $25.6 · target $50 by Aug 2027 · Buy via Investing.com
- Wells Fargo: at $25.6 · target $50 by Aug 2027 · Overweight via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RARE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ultragenyx Pharmaceutical →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.